# Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature

> **NCT06894225** · PHASE2 · SUSPENDED · sponsor: **National Neuroscience Institute** · enrollment: 12 (estimated)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** ACT001

## Key facts

- **NCT ID:** NCT06894225
- **Lead sponsor:** National Neuroscience Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-03-22
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 12 (ESTIMATED)
- **Why stopped:** Study team is finding new fundings for the study
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06894225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06894225, "Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06894225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*